COMPANY

SpyGlass Pharma

HQ: Irvine, CA source · spyglasspharma.com ↗ · West Coast

Clinical Phase 3

Keywords: drug delivery eye diseases glaucoma cataract ophthalmology Ocular Hypertension

Location: Irvine, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

$247.5MRaised (2 yrs)6Trials (company is sponsor)

Timeline

Jul 31, 2026 Trial start Phase 1: Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension source ↗
Feb 9, 2026 Raise IPO: $172.5M (total, as published), announced Feb 9, 2026. Source: company release on GlobeNewswire. source ↗
Oct 28, 2025 Trial start Phase 3: Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone) source ↗
Oct 15, 2025 Trial start Phase 3: Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine) source ↗
Jun 2, 2025 Raise Private equity round — Series D: $75M (total, as published), announced Jun 2, 2025. Source: company release on GlobeNewswire. source ↗
Oct 13, 2023 Trial start Phase 1/Phase 2: Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution source ↗
Mar 16, 2023 Trial start —: Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination source ↗
Apr 21, 2022 Trial start Not phased (device or behavioral study): Evaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular Hypertension or Mild to Moderate Open-angle Glaucoma source ↗

Upcoming milestones

Feb 28, 2027 (ESTIMATED) · Phase 1 · Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension · NCT07641296
Mar 31, 2029 (ESTIMATED) · Phase 3 · Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine) · NCT07218783
May 31, 2029 (ESTIMATED) · Phase 3 · Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone) · NCT07218796
Apr 14, 2031 (ESTIMATED) · · Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination · NCT07154810

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $247.5M. Last 2 years.

Feb 9, 2026 IPO: $172.5M (total, as published), announced Feb 9, 2026. Source: company release on GlobeNewswire. source ↗
Jun 2, 2025 Private equity round — Series D: $75M (total, as published), announced Jun 2, 2025. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 6

Record	Title	Phase	Status	Start	Primary completion
NCT07641296	Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension	Phase 1	Not yet recruiting	Jul 31, 2026	Feb 28, 2027 (estimated)
NCT07218783	Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)	Phase 3	Recruiting	Oct 15, 2025	Mar 31, 2029 (estimated)
NCT07218796	Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)	Phase 3	Recruiting	Oct 28, 2025	May 31, 2029 (estimated)
NCT07154797	Evaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular Hypertension or Mild to Moderate Open-angle Glaucoma	Not phased (device or behavioral study)	Completed	Apr 21, 2022	Dec 13, 2022 (actual)
NCT07154810	Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination	Not listed	Active, not recruiting	Mar 16, 2023	Apr 14, 2031 (estimated)
NCT06120842	Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution	Phase 1/Phase 2	Active, not recruiting	Oct 13, 2023	Jan 31, 2025 (actual)